Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating guselkumab subcutaneously in active psoriatic arthritis, including prior TNF inhibitors; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Psoriatic | Phase 3 | Status: COMPLETED | Results posted: 2020-10-14